Crispr Therapeutics AG vs VF Corp — how do they compare? Crispr Therapeutics AG trades at $53.97 (market cap $5.23B), while VF Corp trades at $14.9 (market cap $5.81B). The key difference: Crispr Therapeutics AG and VF Corp are close in size by market cap, and VF Corp pays a 2.44% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VFC | |
|---|---|---|
Market Cap | $5.23B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $21.55 |
52-Week Low | $44.34 | $12.21 |
Enterprise Value | $3.65B | $10.09B |
Dividend Yield | — | 2.44% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →